Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Gary Gustavsen"'
Autor:
Monica M, Schroll, Arushi, Agarwal, Olivia, Foroughi, Emily, Kong, Omar, Perez, Daryl, Pritchard, Tom, Breur, Kristen, Garner Amanti, Gary, Gustavsen
Publikováno v:
Journal of Personalized Medicine; Volume 12; Issue 7; Pages: 1025
Despite evidence that precision medicine (PM) results in improved patient care, the broad adoption and implementation has been challenging across the United States (US). To better understand the perceived barriers associated with PM adoption, a quant
Publikováno v:
Journal of Personalized Medicine, Vol 11, Iss 196, p 196 (2021)
Journal of Personalized Medicine
Volume 11
Issue 3
Journal of Personalized Medicine
Volume 11
Issue 3
Personalized medicine (PM) approaches have revolutionized healthcare delivery by offering new insights that enable healthcare providers to select the optimal treatment approach for their patients. However, despite the consensus that these approaches
Publikováno v:
Future oncology (London, England). 16(36)
Background: Prior studies have established that broader incorporation of active surveillance, guided by additional prognostic tools, may mitigate the growing economic burden of localized prostate cancer in the USA. This study sought to further explor
Publikováno v:
Journal of Medical Economics. 17:782-791
Traditional pathology techniques alone can be insufficient to reliably distinguish between malignant melanoma, dysplastic nevi, and benign nevi in biopsies of suspicious pigmented lesions. Numerous studies have shown high rates of ambiguity when asse
Autor:
Alyssa Berkowitz, Lajos Pusztai, Adam Brufsky, Christos Hatzis, Brock Schroeder, Gary Gustavsen, G J. Van Londen, Catherine A. Schnabel, Tara Sanft
Publikováno v:
Breast Cancer Management. 8:BMT22
Aim: To prospectively assess the impact of gene expression-based assay Breast Cancer Index (BCI) on extended endocrine therapy (EET) decision-making. Patients & methods: The BCI-tested samples from primary tumors (Stage I–III, hormone receptor posi
Autor:
Kristin Pothier, Gary Gustavsen
Publikováno v:
Personalized Medicine. 10:387-396
We are entering an era of unprecedented complexity in personalized medicine. Therapeutic targets, biomarker detection technologies, regulatory and reimbursement pathways, and commercialization strategies have all reached new levels of intricacy. Thes
Autor:
Bilge Aktas, Tara Sanft, G J. Van Londen, Brock Schroeder, Alyssa Berkowitz, Adam Brufsky, Gary Gustavsen, Christos Hatzis, Lajos Pusztai, Catherine A. Schnabel
Publikováno v:
Journal of Clinical Oncology. 35:25-25
25 Background: Previous research has demonstrated the benefit of EET for HRBC, however, the absolute benefit is modest and commits women to an extra 5 yrs of treatment. The Breast Cancer Index (BCI) is a gene expression-based test that has been valid
Autor:
Gary, Gustavsen, Brock, Schroeder, Patrick, Kennedy, Kristin Ciriello, Pothier, Mark G, Erlander, Catherine A, Schnabel, Haythem, Ali
Publikováno v:
The American journal of managed care. 20(8)
Breast Cancer Index (BCI) is a novel gene expression-based test for patients with estrogen receptor positive (ER+), lymph node negative (LN-) breast cancer that predicts risk of recurrence over 10 years, and also specifically predicts risk of late (
Autor:
Raoul S. Concepcion, Daniel Saltzstein, Arletta van Breda, Neal D. Shore, William Welbourn, Michael K. Brawer, M. Scott Lucia, Nicolas Lewine, Kristin Pothier, Gary Gustavsen
Publikováno v:
Current medical research and opinion. 30(4)
The CCP signature test (Prolaris) quantifies a patient's risk of disease progression and prostate cancer specific mortality using a gene-expression-based cell cycle progression (CCP) score. This study evaluated the potential clinical utility of the C
Autor:
Richard L. Schilsky, Robert T. McCormack, Sean R. Tunis, Ellen V. Sigal, Gary Gustavsen, Lee N. Newcomer, Kristin Pothier, Jeff Allen, Daniel F. Hayes, David F. Ransohoff, Sheila E. Taube, Carolyn C. Compton, Debra G.B. Leonard
Publikováno v:
Science Translational Medicine. 5
Despite prodigious advances in tumor biology research, few tumor-biomarker tests have been adopted as standard clinical practice. This lack of reliable tests stems from a vicious cycle of undervaluation, resulting from inconsistent regulatory standar